Evidence map›Paper›PMID 27553411›Full record

ArticleTuberculosis (Edinburgh, Scotland)2016

Ex-vivo characterization of regulatory T cells in pulmonary tuberculosis patients, latently infected persons, and healthy endemic controls.

Martha Zewdie, Rawleigh Howe, Søren T Hoff, T Mark Doherty, Nahom Getachew, Azeb Tarekegne, Bamlak Tessema, Lawrence Yamuah, Abraham Aseffa, Markos Abebe

Abstract readMulticenter Study
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Emerging patterns of regulatory T cell function in tuberculosis.Clinical and experimental immunology · 2020
    Review
  7. Regulatory T Cells inFrontiers in immunology · 2019
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Martha ZewdieArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia. Electronic address: martha_zg@yahoo.co.uk.
Rawleigh HoweArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Søren T HoffDepartment of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
T Mark DohertyDepartment of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark.
Nahom GetachewArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Azeb TarekegneArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Bamlak TessemaArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Lawrence YamuahArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Abraham AseffaArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Markos AbebeArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia.
Armauer Hansen Research Institute · ETStatens Serum Institut · DK

Funding

Ethiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026
$3.4M
FIC NIH HHS D43 TW009127
6 · The paper itself

Abstract

backgroundRegulatory T cells (Treg) are an essential arm of adaptive immunity not only in tolerance and autoimmunity but also in infectious diseases. In Tuberculosis (TB), it has been suggested that the frequency of Tregs is higher in the blood of TB patients when compared to healthy controls with subsequent decline after treatment. However, with the discovery that FOXP3, the hallmark marker of Tregs, is not exclusive to Tregs and the lack of specific markers for Tregs, it has been a challenge to fully understand the role of Tregs in TB.

methodWe isolated PBMC from smear positive TB patients (TB, N = 13) before and after treatment, latent TB infected participants (LTBI, N = 8), and healthy endemic controls (EC, N = 9) and evaluated the frequency of different populations of Tregs and expression of FOXP3 by flowcytometry using six markers.

resultsThe findings in this study showed that the association of Treg frequency with TB disease depends on the phenotypic markers used. While the frequency of CD4(+)CD25(+/hi) T cells was higher in TB patients compared to LTBI individuals, there was no difference in the frequency of CD4(+)CD25(+)FOXP3(+)CD127(lo) Treg among TB, LTBI, or EC. However, delineation of Tregs into active and naïve subsets revealed a significant increase in FOXP3 expression in active primed Tregs (CD4(+)CD25(+)FOXP3(+)CD127(lo)CD45RO(+)Ki-67(+)) of TB patients compared to LTBI and EC; and a significantly higher frequency of resting primed (CD45RO(+)Ki-67(-)) Treg in QuantiFERON negative EC compared to TB patients. After treatment completion, there was a significant decline in the frequency of active primed Treg, median (IQR) from 12.4% (9.5-21.9) of Tregs to 9.3% (7.0-12.2); P = 0.003 Wilcoxon signed rank test. We conclude that Treg subsets may be differentially regulated and expressed in TB disease, cure, and infection.

Indexed as

AdolescentAdultAntitubercular AgentsBiomarkersCase-Control StudiesFemaleFlow CytometryFollow-Up StudiesForkhead Transcription FactorsHumansImmunophenotypingLatent TuberculosisMaleMiddle AgedT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsAntitubercular AgentsBiomarkersForkhead Transcription FactorsFOXP3 protein, humanFOXP3Regulatory T cellsTuberculosis

Identifiers

PMID27553411
PMCPMC5111553
OpenAlexW2474300931

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.